APO Research
Talk to an analyst

APO RESEARCH · REPORT

Flu (Influenza) Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Flu (Influenza) Vaccine Market Outlook and Growth Opportunities 2026

2 January 2026197 pages

Choose your research edition.

Industry ResearchFlu (Influenza) Vaccine Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Flu (Influenza) Vaccine Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Flu (Influenza) Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Flu (Influenza) Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Flu (Influenza) Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Flu (Influenza) Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Flu (Influenza) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Flu (Influenza) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Flu (Influenza) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Flu (Influenza) Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Flu (Influenza) Vaccine market include Adimmune, Aimei Hissen, Aleph Biomedical, CCBIO, Changsheng Biological, Hualan Bio, Simcere Vaxtec, SINOVAC and SIOBP, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Flu (Influenza) Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Flu (Influenza) Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Flu (Influenza) Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Flu (Influenza) Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Flu (Influenza) Vaccine Segment by Company

Adimmune

Aimei Hissen

Aleph Biomedical

CCBIO

Changsheng Biological

Hualan Bio

Simcere Vaxtec

SINOVAC

SIOBP

Tianyuan Bio-pharma(Novartis)

ZYAK

GSK

SANOFI

Flu (Influenza) Vaccine Segment by Type

Subunit Influenza Vaccine

Quadrivalent Influenza Vaccine

Split Influenza Vaccine

Pandemic Influenza Vaccine

Flu (Influenza) Vaccine Segment by Application

For Children (6 months to 3 years)

For Adults and Children over 3 years

Flu (Influenza) Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Flu (Influenza) Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Flu (Influenza) Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Flu (Influenza) Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Flu (Influenza) Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Flu (Influenza) Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Flu (Influenza) Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Flu (Influenza) Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Flu (Influenza) Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Flu (Influenza) Vaccine industry.

Chapter 3: Detailed analysis of Flu (Influenza) Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Flu (Influenza) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Flu (Influenza) Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Flu (Influenza) Vaccine Industry Trends Table 2. Flu (Influenza) Vaccine Industry Drivers Table 3. Flu (Influenza) Vaccine Industry Opportunities and Challenges Table 4. Flu (Influenza) Vaccine Industry Restraints Table 5. Global Flu (Influenza) Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Flu (Influenza) Vaccine Revenue Share by Company (2021-2026) Table 7. Global Flu (Influenza) Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Flu (Influenza) Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Flu (Influenza) Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Flu (Influenza) Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Flu (Influenza) Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Flu (Influenza) Vaccine Company, Product Type & Application Table 13. Global Flu (Influenza) Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Flu (Influenza) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Subunit Influenza Vaccine Table 18. Significant Companies of Quadrivalent Influenza Vaccine Table 19. Significant Companies of Split Influenza Vaccine Table 20. Significant Companies of Pandemic Influenza Vaccine Table 21. Global Flu (Influenza) Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Flu (Influenza) Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Flu (Influenza) Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Flu (Influenza) Vaccine Sales Volume Share by Type (2021-2026) Table 25. Global Flu (Influenza) Vaccine Sales Volume Share by Type (2027-2032) Table 26. Global Flu (Influenza) Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Flu (Influenza) Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Flu (Influenza) Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Flu (Influenza) Vaccine Sales Value Share by Type (2021-2026) Table 30. Global Flu (Influenza) Vaccine Sales Value Share by Type (2027-2032) Table 31. Significant Companies of For Children (6 months to 3 years) Table 32. Significant Companies of For Adults and Children over 3 years Table 33. Global Flu (Influenza) Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Flu (Influenza) Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Flu (Influenza) Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Flu (Influenza) Vaccine Sales Volume Share by Application (2021-2026) Table 37. Global Flu (Influenza) Vaccine Sales Volume Share by Application (2027-2032) Table 38. Global Flu (Influenza) Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Flu (Influenza) Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Flu (Influenza) Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Flu (Influenza) Vaccine Sales Value Share by Application (2021-2026) Table 42. Global Flu (Influenza) Vaccine Sales Value Share by Application (2027-2032) Table 43. Global Flu (Influenza) Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Flu (Influenza) Vaccine Sales by Region (2021-2026) & (K Units) Table 45. Global Flu (Influenza) Vaccine Sales Market Share by Region (2021-2026) Table 46. Global Flu (Influenza) Vaccine Sales by Region (2027-2032) & (K Units) Table 47. Global Flu (Influenza) Vaccine Sales Market Share by Region (2027-2032) Table 48. Global Flu (Influenza) Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Flu (Influenza) Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Flu (Influenza) Vaccine Sales Value Share by Region (2021-2026) Table 51. Global Flu (Influenza) Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Flu (Influenza) Vaccine Sales Value Share by Region (2027-2032) Table 53. Global Flu (Influenza) Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Flu (Influenza) Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Flu (Influenza) Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Flu (Influenza) Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Flu (Influenza) Vaccine Sales by Country (2021-2026) & (K Units) Table 58. Global Flu (Influenza) Vaccine Sales Market Share by Country (2021-2026) Table 59. Global Flu (Influenza) Vaccine Sales by Country (2027-2032) & (K Units) Table 60. Global Flu (Influenza) Vaccine Sales Market Share by Country (2027-2032) Table 61. Global Flu (Influenza) Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Flu (Influenza) Vaccine Sales Value Market Share by Country (2021-2026) Table 63. Global Flu (Influenza) Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Flu (Influenza) Vaccine Sales Value Market Share by Country (2027-2032) Table 65. Adimmune Company Information Table 66. Adimmune Business Overview Table 67. Adimmune Flu (Influenza) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Adimmune Flu (Influenza) Vaccine Product Portfolio Table 69. Adimmune Recent Development Table 70. Aimei Hissen Company Information Table 71. Aimei Hissen Business Overview Table 72. Aimei Hissen Flu (Influenza) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Aimei Hissen Flu (Influenza) Vaccine Product Portfolio Table 74. Aimei Hissen Recent Development Table 75. Aleph Biomedical Company Information Table 76. Aleph Biomedical Business Overview Table 77. Aleph Biomedical Flu (Influenza) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Aleph Biomedical Flu (Influenza) Vaccine Product Portfolio Table 79. Aleph Biomedical Recent Development Table 80. CCBIO Company Information Table 81. CCBIO Business Overview Table 82. CCBIO Flu (Influenza) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. CCBIO Flu (Influenza) Vaccine Product Portfolio Table 84. CCBIO Recent Development Table 85. Changsheng Biological Company Information Table 86. Changsheng Biological Business Overview Table 87. Changsheng Biological Flu (Influenza) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Changsheng Biological Flu (Influenza) Vaccine Product Portfolio Table 89. Changsheng Biological Recent Development Table 90. Hualan Bio Company Information Table 91. Hualan Bio Business Overview Table 92. Hualan Bio Flu (Influenza) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Hualan Bio Flu (Influenza) Vaccine Product Portfolio Table 94. Hualan Bio Recent Development Table 95. Simcere Vaxtec Company Information Table 96. Simcere Vaxtec Business Overview Table 97. Simcere Vaxtec Flu (Influenza) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Simcere Vaxtec Flu (Influenza) Vaccine Product Portfolio Table 99. Simcere Vaxtec Recent Development Table 100. SINOVAC Company Information Table 101. SINOVAC Business Overview Table 102. SINOVAC Flu (Influenza) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. SINOVAC Flu (Influenza) Vaccine Product Portfolio Table 104. SINOVAC Recent Development Table 105. SIOBP Company Information Table 106. SIOBP Business Overview Table 107. SIOBP Flu (Influenza) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. SIOBP Flu (Influenza) Vaccine Product Portfolio Table 109. SIOBP Recent Development Table 110. Tianyuan Bio-pharma(Novartis) Company Information Table 111. Tianyuan Bio-pharma(Novartis) Business Overview Table 112. Tianyuan Bio-pharma(Novartis) Flu (Influenza) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Tianyuan Bio-pharma(Novartis) Flu (Influenza) Vaccine Product Portfolio Table 114. Tianyuan Bio-pharma(Novartis) Recent Development Table 115. ZYAK Company Information Table 116. ZYAK Business Overview Table 117. ZYAK Flu (Influenza) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. ZYAK Flu (Influenza) Vaccine Product Portfolio Table 119. ZYAK Recent Development Table 120. GSK Company Information Table 121. GSK Business Overview Table 122. GSK Flu (Influenza) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. GSK Flu (Influenza) Vaccine Product Portfolio Table 124. GSK Recent Development Table 125. SANOFI Company Information Table 126. SANOFI Business Overview Table 127. SANOFI Flu (Influenza) Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. SANOFI Flu (Influenza) Vaccine Product Portfolio Table 129. SANOFI Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Flu (Influenza) Vaccine Distributors List Table 133. Flu (Influenza) Vaccine Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Flu (Influenza) Vaccine Product Image Figure 2. Global Flu (Influenza) Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Flu (Influenza) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Flu (Influenza) Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Flu (Influenza) Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Flu (Influenza) Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Subunit Influenza Vaccine Image Figure 10. Quadrivalent Influenza Vaccine Image Figure 11. Split Influenza Vaccine Image Figure 12. Pandemic Influenza Vaccine Image Figure 13. Global Flu (Influenza) Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Flu (Influenza) Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Flu (Influenza) Vaccine Sales Volume Share by Type (2021-2032) Figure 16. Global Flu (Influenza) Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Flu (Influenza) Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Flu (Influenza) Vaccine Sales Value Share by Type (2021-2032) Figure 19. For Children (6 months to 3 years) Image Figure 20. For Adults and Children over 3 years Image Figure 21. Global Flu (Influenza) Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Flu (Influenza) Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Flu (Influenza) Vaccine Sales Volume Share by Application (2021-2032) Figure 24. Global Flu (Influenza) Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Flu (Influenza) Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Flu (Influenza) Vaccine Sales Value Share by Application (2021-2032) Figure 27. Global Flu (Influenza) Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Flu (Influenza) Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Flu (Influenza) Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Flu (Influenza) Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Flu (Influenza) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. North America Flu (Influenza) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Flu (Influenza) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Flu (Influenza) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Flu (Influenza) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Flu (Influenza) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Flu (Influenza) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. South America Flu (Influenza) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Flu (Influenza) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Flu (Influenza) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Flu (Influenza) Vaccine Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Flu (Influenza) Vaccine Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Subunit Influenza Vaccine
  • Quadrivalent Influenza Vaccine
  • Split Influenza Vaccine
  • Pandemic Influenza Vaccine
Applications
  • For Children (6 months to 3 years)
  • For Adults and Children over 3 years
Companies covered
  • Adimmune
  • Aimei Hissen
  • Aleph Biomedical
  • CCBIO
  • Changsheng Biological
  • Hualan Bio
  • Simcere Vaxtec
  • SINOVAC
  • SIOBP
  • Tianyuan Bio-pharma(Novartis)
  • ZYAK
  • GSK
  • SANOFI

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Flu (Influenza) Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Flu (Influenza) Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Flu (Influenza) Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Flu (Influenza) Vaccine Market Dynamics
  1. 2.1 Flu (Influenza) Vaccine Industry Trends
  2. 2.2 Flu (Influenza) Vaccine Industry Drivers
  3. 2.3 Flu (Influenza) Vaccine Industry Opportunities and Challenges
  4. 2.4 Flu (Influenza) Vaccine Industry Restraints
3 Flu (Influenza) Vaccine Market by Company
  1. 3.1 Global Flu (Influenza) Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Flu (Influenza) Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Flu (Influenza) Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Flu (Influenza) Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Flu (Influenza) Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Flu (Influenza) Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Flu (Influenza) Vaccine Company Product Type and Application
  8. 3.8 Global Flu (Influenza) Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Flu (Influenza) Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Flu (Influenza) Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Flu (Influenza) Vaccine Market by Type
  1. 4.1 Flu (Influenza) Vaccine Type Introduction
  2. 4.1.1 Subunit Influenza Vaccine
  3. 4.1.2 Quadrivalent Influenza Vaccine
  4. 4.1.3 Split Influenza Vaccine
  5. 4.1.4 Pandemic Influenza Vaccine
  6. 4.2 Global Flu (Influenza) Vaccine Sales Volume by Type
  7. 4.2.1 Global Flu (Influenza) Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Flu (Influenza) Vaccine Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Flu (Influenza) Vaccine Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Flu (Influenza) Vaccine Sales Value by Type
  11. 4.3.1 Global Flu (Influenza) Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Flu (Influenza) Vaccine Sales Value by Type (2021-2032)
  13. 4.3.3 Global Flu (Influenza) Vaccine Sales Value Share by Type (2021-2032)
5 Flu (Influenza) Vaccine Market by Application
  1. 5.1 Flu (Influenza) Vaccine Application Introduction
  2. 5.1.1 For Children (6 months to 3 years)
  3. 5.1.2 For Adults and Children over 3 years
  4. 5.2 Global Flu (Influenza) Vaccine Sales Volume by Application
  5. 5.2.1 Global Flu (Influenza) Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Flu (Influenza) Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Flu (Influenza) Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Flu (Influenza) Vaccine Sales Value by Application
  9. 5.3.1 Global Flu (Influenza) Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Flu (Influenza) Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Flu (Influenza) Vaccine Sales Value Share by Application (2021-2032)
6 Flu (Influenza) Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Flu (Influenza) Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Flu (Influenza) Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Flu (Influenza) Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Flu (Influenza) Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Flu (Influenza) Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Flu (Influenza) Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Flu (Influenza) Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Flu (Influenza) Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Flu (Influenza) Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Flu (Influenza) Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Flu (Influenza) Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Flu (Influenza) Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Flu (Influenza) Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Flu (Influenza) Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Flu (Influenza) Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Flu (Influenza) Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Flu (Influenza) Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Flu (Influenza) Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Flu (Influenza) Vaccine Sales Value Share by Country, 2025 VS 2032
7 Flu (Influenza) Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Flu (Influenza) Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Flu (Influenza) Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Flu (Influenza) Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Flu (Influenza) Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Flu (Influenza) Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Flu (Influenza) Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Flu (Influenza) Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Flu (Influenza) Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Flu (Influenza) Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Flu (Influenza) Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Flu (Influenza) Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Adimmune
  2. 8.1.1 Adimmune Company Information
  3. 8.1.2 Adimmune Business Overview
  4. 8.1.3 Adimmune Flu (Influenza) Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Adimmune Flu (Influenza) Vaccine Product Portfolio
  6. 8.1.5 Adimmune Recent Developments
  7. 8.2 Aimei Hissen
  8. 8.2.1 Aimei Hissen Company Information
  9. 8.2.2 Aimei Hissen Business Overview
  10. 8.2.3 Aimei Hissen Flu (Influenza) Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Aimei Hissen Flu (Influenza) Vaccine Product Portfolio
  12. 8.2.5 Aimei Hissen Recent Developments
  13. 8.3 Aleph Biomedical
  14. 8.3.1 Aleph Biomedical Company Information
  15. 8.3.2 Aleph Biomedical Business Overview
  16. 8.3.3 Aleph Biomedical Flu (Influenza) Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Aleph Biomedical Flu (Influenza) Vaccine Product Portfolio
  18. 8.3.5 Aleph Biomedical Recent Developments
  19. 8.4 CCBIO
  20. 8.4.1 CCBIO Company Information
  21. 8.4.2 CCBIO Business Overview
  22. 8.4.3 CCBIO Flu (Influenza) Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 CCBIO Flu (Influenza) Vaccine Product Portfolio
  24. 8.4.5 CCBIO Recent Developments
  25. 8.5 Changsheng Biological
  26. 8.5.1 Changsheng Biological Company Information
  27. 8.5.2 Changsheng Biological Business Overview
  28. 8.5.3 Changsheng Biological Flu (Influenza) Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Changsheng Biological Flu (Influenza) Vaccine Product Portfolio
  30. 8.5.5 Changsheng Biological Recent Developments
  31. 8.6 Hualan Bio
  32. 8.6.1 Hualan Bio Company Information
  33. 8.6.2 Hualan Bio Business Overview
  34. 8.6.3 Hualan Bio Flu (Influenza) Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Hualan Bio Flu (Influenza) Vaccine Product Portfolio
  36. 8.6.5 Hualan Bio Recent Developments
  37. 8.7 Simcere Vaxtec
  38. 8.7.1 Simcere Vaxtec Company Information
  39. 8.7.2 Simcere Vaxtec Business Overview
  40. 8.7.3 Simcere Vaxtec Flu (Influenza) Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Simcere Vaxtec Flu (Influenza) Vaccine Product Portfolio
  42. 8.7.5 Simcere Vaxtec Recent Developments
  43. 8.8 SINOVAC
  44. 8.8.1 SINOVAC Company Information
  45. 8.8.2 SINOVAC Business Overview
  46. 8.8.3 SINOVAC Flu (Influenza) Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 SINOVAC Flu (Influenza) Vaccine Product Portfolio
  48. 8.8.5 SINOVAC Recent Developments
  49. 8.9 SIOBP
  50. 8.9.1 SIOBP Company Information
  51. 8.9.2 SIOBP Business Overview
  52. 8.9.3 SIOBP Flu (Influenza) Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 SIOBP Flu (Influenza) Vaccine Product Portfolio
  54. 8.9.5 SIOBP Recent Developments
  55. 8.10 Tianyuan Bio-pharma(Novartis)
  56. 8.10.1 Tianyuan Bio-pharma(Novartis) Company Information
  57. 8.10.2 Tianyuan Bio-pharma(Novartis) Business Overview
  58. 8.10.3 Tianyuan Bio-pharma(Novartis) Flu (Influenza) Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Tianyuan Bio-pharma(Novartis) Flu (Influenza) Vaccine Product Portfolio
  60. 8.10.5 Tianyuan Bio-pharma(Novartis) Recent Developments
  61. 8.11 ZYAK
  62. 8.11.1 ZYAK Company Information
  63. 8.11.2 ZYAK Business Overview
  64. 8.11.3 ZYAK Flu (Influenza) Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 ZYAK Flu (Influenza) Vaccine Product Portfolio
  66. 8.11.5 ZYAK Recent Developments
  67. 8.12 GSK
  68. 8.12.1 GSK Company Information
  69. 8.12.2 GSK Business Overview
  70. 8.12.3 GSK Flu (Influenza) Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 GSK Flu (Influenza) Vaccine Product Portfolio
  72. 8.12.5 GSK Recent Developments
  73. 8.13 SANOFI
  74. 8.13.1 SANOFI Company Information
  75. 8.13.2 SANOFI Business Overview
  76. 8.13.3 SANOFI Flu (Influenza) Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 SANOFI Flu (Influenza) Vaccine Product Portfolio
  78. 8.13.5 SANOFI Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Flu (Influenza) Vaccine Value Chain Analysis
  2. 9.1.1 Flu (Influenza) Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Flu (Influenza) Vaccine Sales Mode & Process
  6. 9.2 Flu (Influenza) Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Flu (Influenza) Vaccine Distributors
  9. 9.2.3 Flu (Influenza) Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst